SCHEMBL12374470

SCHEMBL12374470

Cc1cc(=O)nc(NC(=O)NCC(O)CNC(=O)Nc2nc(=O)cc(C)[nH]2)[nH]1

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 14/20 0.38
▸ MAPT P10636 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12374472 0.89 ABL1 (0.36) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL12374457 0.85 ABL1 (0.40) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21216730 0.84 ABL1 (0.51) ABL1
SCHEMBL27047910 0.83 ABL1 (0.39) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20806159 0.82 RAB9A (0.41) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL17790096 0.81 ABL1 (0.33) ABL1
SCHEMBL12374475 0.81 HTT (0.34) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL16621841 0.81 ALDH1A1 (0.38) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL12462223 0.81 ABL1 (0.38) ABL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL14477568 0.80 ABL1 (0.33) ABL1MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11141368-B2 Cosmetic composition, cosmetic treatment method, kit, and compound L'OREAL (FR) 2021-10-12 — — US disclosed
US-10813866-B2 Cosmetic composition, cosmetic treatment method, kit, and compound L'OREAL (FR) 2020-10-27 — — US disclosed
EP-2521530-B1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND OREAL (FR) 2019-06-26 — — EP disclosed
US-8575341-B2 Cosmetic composition, cosmetic treatment method, and compound L'OREAL (FR) 2013-11-05 — — US disclosed
US-8575341-B2 Cosmetic composition, cosmetic treatment method, and compound L'OREAL (FR) 2013-11-05 — — US disclosed
US-20130017162-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND L'OREAL (FR) 2013-01-17 — — US disclosed
US-20130017162-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND L'OREAL (FR) 2013-01-17 — — US disclosed
US-20110189118-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND L'OREAL (FR) 2011-08-04 — — US disclosed
US-20110189118-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND L'OREAL (FR) 2011-08-04 — — US disclosed
WO-2011080494-A2 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND L'OREAL (FR) 2011-07-07 — — WO disclosed
WO-2010001041-A2 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND L'OREAL (FR) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017162-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND KRT18, KIT, TYR ABL1 1039/4885MAPT 3414/4885MEN1 1910/4885
US-20110189118-A1 COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND KRT18, MC1R, C1R ABL1 4705/4885MAPT 2742/4885MEN1 1323/4885
US-10813866-B2 Cosmetic composition, cosmetic treatment method, kit, and compound KRT18, KIT, TYR ABL1 1039/4885MAPT 3414/4885MEN1 1910/4885
US-11141368-B2 Cosmetic composition, cosmetic treatment method, kit, and compound KRT18, KIT, TYR ABL1 1039/4885MAPT 3414/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback